Efficacy and safety of 125I intraluminal irradiation combined with lenvatinib in treatment of progressive extrahepatic cholangiocarcinoma
10.3969/j.issn.1001-5256.2023.10.019
- VernacularTitle:125I腔内照射联合仑伐替尼治疗进展期肝外胆管癌的效果和安全性分析
- Author:
Xingshu ZHU
1
;
Pengfei CHEN
1
;
Mengfan ZHANG
1
;
Fangzheng LI
1
;
Jinwei CHEN
1
;
Wenguang ZHANG
1
;
Xuhua DUAN
1
;
Jianzhuang REN
1
;
Xinwei HAN
1
Author Information
1. Department of Interventional Radiology， The First Affiliated Hospital of Zhengzhou University， Zhengzhou 450052， China
- Publication Type:Journal Article
- Keywords:
Cholangiocarcinoma;
Iodine Radioisotopes;
Lenvatinib;
Radiology， Interventional
- From:
Journal of Clinical Hepatology
2023;39(10):2406-2412
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the efficacy and safety of 125I intraluminal irradiation combined with lenvatinib in the treatment of progressive extrahepatic cholangiocarcinoma. MethodsA retrospective analysis was performed for 25 patients with progressive extrahepatic cholangiocarcinoma who attended Department of Interventional Radiology， The First Affiliated Hospital of Zhengzhou University， from January 2018 to November 2021， and according to the treatment modality， they were divided into combination group with 13 patients （125I intraluminal irradiation combined with lenvatinib） and control group （125I intraluminal irradiation alone）. The two groups were compared in terms of technical success rates， changes in liver function， stent patency， survival time， and incidence rates of adverse events. The independent－samples t test was used for comparison of normally distributed continuous data between two groups， and the Wilcoxon rank－sum test was used for comparison of continuous data with skewed distribution between two groups； the Fisher’s exact test was used for comparison of categorical data between groups. The Kaplan－Meier method and the log－rank test were used to evaluate survival time and stent patency. ResultsAll patients had successful implantation of biliary stents and 125I particles， with a technical success rate of 100%. After 1 month of treatment， both groups had significant improvements in the serum levels of total bilirubin， direct bilirubin， alanine aminotransferase， and aspartate aminotransferase （all P<0.05）. There were significant differences between the control group and the combination group in the duration of stent patency （7.0 months vs 9.5 months， P=0.022） and median survival time （11.5 months vs 15.6 months， P=0.008）. There were no intolerable adverse events in the combination group during treatment. ConclusionCompared with 125I intraluminal irradiation alone， 125I intraluminal irradiation combined with lenvatinib has better efficacy and is a safe and effective treatment regimen for progressive extrahepatic cholangiocarcinoma.
